Tailorx trial data supports use of Oncotype DX test in patients with early stage brea

[News]

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.

More... (http://www.news-medical.net/news/20150929/Tailorx-trial-data-supports-use-of-Oncotype-DX-test-in-patients-with-early-stage-breast-cancer.aspx)